Sentence examples for broader trial from inspiring English sources

As prosecution and defence prepare to call witnesses to support their arguments on sentencing, here are a few thoughts about Judge Masipa's options, and the broader trial: Jail term.

The intervention needed further refinement prior to a broader trial.

Many specific aspects of the broader trial design, including details of randomisation and blinding, are addressed elsewhere in the CONSORT checklist.

We explored whether the type of Network affected the level of activity, but found no consistent pattern; this target was reached ahead of schedule and indeed exceeded, demonstrating that a coordinated and targeted effort can result in increased recruitment, geographically broader trial participation and timely delivery of research studies, while maintaining high standards of research quality.

Broader trials are needed to confirm the results, and it will most likely be years before the product is publicly available, but if produced on a large scale the gel would cost less than 25 cents per application, the lead investigators estimated.

In addition, several other trials in which diabetic patients constituted only subgroups within broader trials of aspirin prophylaxis, yielded conflicting results [ 44– 44].

In summary, the currently available evidence on aspirin for CVD prevention includes three trials conducted specifically in patients with diabetes and six other trials in which patients with diabetes constitute subgroups within broader trials of aspirin prophylaxis.

The dispute over the United Nations mission developed because the team appointed by Mr. Annan, which included two veterans of relief work, and suggestions he made that the inquiry could go beyond the operations in Jenin ignited Israelis' fears that the mission would expand into a broad trial.

Prior to 2010, randomized controlled trials (RCTs) of antibiotic therapy for ABSSSI used broad trial inclusion criteria and utilized investigator-determined clinical resolution, 7 to 14 days after the end of therapy, as the primary outcome measure.

This may overcome some of the organisational difficulties of maintaining broad trial portfolios in rare tumours.

For one factorial trial, 15 where the data were not available to perform this, only the broad trial comparisons (main effects) were included in the analyses.